Pacylex Pharmaceuticals, Inc.

@pacylex

Emerging biotech oncology company. Clear path to an IND. Looking for Series A investors to fund clinical development of first-in-class product.

Edmonton, Canada
Vrijeme pridruživanja: prosinac 2019.

Tweetovi

Blokirali ste korisnika/cu @pacylex

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @pacylex

  1. 4. velj

    Exciting preclinical data and novel mechanism of action for PCLX-001 positions Pacylex well for 2020.

    Poništi
  2. 3. velj

    An Exciting New Mechanism: several reasons PCLX-001 might be a gem

    Poništi
  3. 3. velj

    What Are the Differences Between Lymphocytic and Myelogenous Leukemia?

    Poništi
  4. 2. velj

    PCLX-001, qualifies for both Orphan Drug designation and Fast Track status in the US and EU

    Poništi
  5. 30. sij

    AI offers potential as diagnostic tool for acute myeloid leukemia

    Poništi
  6. 20. sij

    PCLX-001 is taken orally once per day with high bioavailability providing a significant dosing and convenience advantage for patients

    Poništi
  7. 18. sij

    Video: Pacylex Pharmaceuticals completes its 'landmark' toxicology dosing

    Poništi
  8. 17. sij

    Pacylex- Data from four different preclinical models suggest that PCLX-001 has robust efficacy in leukemia and lymphoma

    Poništi
  9. 15. sij

    Phase I Human Clinical Studies - Targeting Blood Cancer with Novel Mechanism and Precision Approach Expected to Begin This Year.

    Poništi
  10. 15. sij
    Poništi
  11. 15. sij

    Pacylex shared highlights about their potential gem in its pipeline this week at the Biotech Showcase.

    Poništi
  12. 15. sij

    Pacylex Discussed new oncology targets and a drug candidate at Biotech Showcase this week.

    Poništi
  13. 14. sij
    Poništi
  14. 13. sij

    Pacylex Discusses new oncology target and drug candidate at Biotech Showcase - today at 4 pm PST

    Poništi
  15. 12. sij

    Pacylex Discusses new oncology target and drug candidate at Biotech Showcase

    Poništi
  16. 11. sij

    The Pacylex Gem: Looking forward to Biotech Showcase!

    Poništi
  17. 11. sij
    Poništi
  18. 10. sij

    Over $500,000 CAD was raised to support the development of Pacylex's lead drug, PCLX-001, currently on track for patient dosing next year.

    Poništi
  19. 10. sij
    Poništi
  20. 10. sij

    Pacylex Targeting Cancer with Novel Mechanism and Precision Approach

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·